Recombinant Monoclonal Antibody Veterinary

anticorps monoclonaux recombinants

Recombinant Antibody by PHAGE DISPLAY (several species)

An efficient and sophisticated technology, the phage display allows the generation of recombinant antibodies from naive or immune banks built from immunized animals or donors. In addition to providing the ability to test a large number of clones thanks to the high throughput screening and access to nucleotide sequences early in the process, this technology allows the development of monoclonal antibodies all types of species (dogs, cats, pigs, etc.).

BIOTEM does not claim any intellectual properties nor any other rights on the developed antibodies.

The phage display is also a technology for the generation of high quality candidates for human and veterinary therapeutic applications.

  • Immune library from immunized animals or donors
  • High throughput screening system
  • Sequencing at early stage
  • Recombinant antibody production (several formats available)
  • Project


    1. Project Specifications

    For each project, our team explores with the client the challenges of the project and defines together the specifications.

    • The target of interest : membrane protein, peptide, small molecule, post-translational modifications, etc.
    • Therapeutic Applications (Veterinary)
    • Specifications : Available material, specificity, deadlines, etc.

    Considering these multiple parameters, BIOTEM proposes tailor-made strategies to meet the client's needs and guarantee the success of the project.

  • Immunization


    2. Immunization

    Depending on the client's specifications, BIOTEM has a wide range of proven immunization strategies to obtain high affinity and specificity antibodies. Specific methods are developed to ensure that the appropriate immune response is achieved. At the end of this phase BIOTEM will be able to offer a contract with guaranteed results. The client will also have the possibility to test the sera in his application.

    • Protein Immunization : From the production of the recombinant protein (transient transfection in CHO) to its preparation for immunization.
    • Peptide Immunization : Immunization with peptides is a relevant strategy for the generation of antibodies directed against selected epitopes. This approach also reduces the need for sophisticated protein preparations for immunization.
    • Non-exhaustive list
  • Library &

    Phage Display

    3. Library & Phage Display

    Unlike naive or synthetic libraries, BIOTEM proposes the construction of an immune library, in VHH / scFv format, focused on the target of interest combined with high throughput screening (or bio-panning) by phage display. This optimizes the chances of success in obtaining high affinity and high specificity antibodies.
    • Selection of a large number of VHH / scFv candidates (VH+VL only)
    • Optimized screening with different stringency conditions (direct, competitive, subtractive, etc.)
    • Immediate access to sequences(single clones - redundancy analysis)
    • Production, Purification and Characterization of candidates (reactivity, affinity, etc.)

    At the end of this phase the client will have the opportunity to test the VHH / scFv and select the best candidates for the reformatting phase in full Ig format or other formats.

  • Reformatting

    & engineering

    4. Reformatting

    This step allows the transition from VHH / scFv to full immunoglobulin format thanks to a fully integrated platform for the production of recombinant antibodies in mammalian cells (CHO). Learn more

    • Several Isotypes
    • Sequence Optimization
    • Antibody Engineering (Isotype, mutations, Fc-fusion protein, Bispecific antibodies, Fab, etc.)
    • Variants (Chimerization, humanization, etc.)
    • Production & Purification (pilot study).

    The CLIENT will decide which candidates to produce in large scales.

  • Production &


    5. Production & purification

    Large scale productions are available with our CHO cell Platform. Learn more

    • From milligram to several grams
    • Low endotoxin Conditions (< 10 EU/mg ; < 1 EU/mg)
    • Serum free System
    • Quality Control (Concentration, purity, affinity, aggregation, stability, etc.).


  • *Required Fields
  • The information collected from this form is saved and transmitted to the staff of our company responsible for processing your message. See our personal data protection policy.
    You have a right of access, rectification and opposition to data concerning you, which you can exercise by going to this page : Contact form responsible for processing.